Palbociclib + Everolimus + Exemestane
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
Trial Timeline
Aug 24, 2016 → Sep 1, 2021
NCT ID
NCT02871791About Palbociclib + Everolimus + Exemestane
Palbociclib + Everolimus + Exemestane is a phase 1/2 stage product being developed by Pfizer for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. The current trial status is completed. This product is registered under clinical trial identifier NCT02871791. Target conditions include Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02871791 | Phase 1/2 | Completed |
Competing Products
20 competing products in Human Epidermal Growth Factor 2 Negative Carcinoma of Breast